Literature DB >> 28946127

Simultaneous determination of cucurbitacin B and cucurbitacin E in rat plasma by UHPLC-MS/MS: A pharmacokinetics study after oral administration of cucurbitacin tablets.

Zhibin Wang1, Wenbo Zhu1, Mingjie Gao2, Chengcui Wu2, Chunjuan Yang2, Jing Yang3, Gaosong Wu1, Bingyou Yang1, Haixue Kuang4.   

Abstract

Cucurbitacin B (CuB) and cucurbitacin E (CuE) are tetracyclic triterpene compounds from Cucurbitaceae, and the main bioactive compounds of cucurbitacins tablets that used to treatment of chronic hepatitis. Pharmacological research has been very comprehensive, and there are few studies on pharmacokinetics, especially about CuE. An Ultra High Performance Liquid Chromatography-tandem Mass Spectrometry (UHPLC-MS/MS) method with high selectivity, simplicity and sensitivity has been used for quantitative analysis of Cucurbitacin B (CuB) and cucurbitacin E (CuE). Plasma samples were pretreatment by Liquid-liquid extraction (LLE) method with dichloromethane. The chromatographic separation was achieved on a C18 column (Agilent Eclipse Plus, 1.8μm, 50×2.1mm) using gradient elution with water - methanol at a flow rate of 0.3mL/min and the column temperature was set at 30°C. The method was validated according to FDA guidelines. Lower limit of quantification (LLOQ) was 1.60ng/mL for CuB and 1.58ng/mL for CuE. Correlation coefficients of CuB and CuE were more than 0.99 in rat plasma. All values of intra-day and inter-day precision (RSD%) were not exceeded 15%, the accuracy (RE%) were within -5.57 to 5.20% for CuB and -3.33 to 7.37% for CuE. The mean extraction recoveries were more than 80%. Pharmacokinetic parameters were also evaluated by UHPLC-MS/MS method. The results suggestion that this method was successfully applied to pharmacokinetic study of CuB and CuE in rat plasma after oral administration cucurbitacin tablets. Published by Elsevier B.V.

Entities:  

Keywords:  Cucurbitacin B; Cucurbitacin e; Pharmacokinetics; UHPLC-MS/MS

Mesh:

Substances:

Year:  2017        PMID: 28946127     DOI: 10.1016/j.jchromb.2017.09.024

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

Review 1.  Use of cucurbitacins for lung cancer research and therapy.

Authors:  Min Liu; Qijia Yan; Bi Peng; Yuan Cai; Shuangshuang Zeng; Zhijie Xu; Yuanliang Yan; Zhicheng Gong
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-06       Impact factor: 3.333

2.  Cell-modified plasmonic interface for the signal-amplified detection of Cucurbitacin E.

Authors:  Yaofei Chen; Shuihua Peng; Peili Zhao; Lei Chen; Gui-Shi Liu; Dongyun Ouyang; Yunhan Luo; Zhe Chen
Journal:  Biomed Opt Express       Date:  2021-12-10       Impact factor: 3.732

3.  A new sensitive UPLC-MS/MS method for the determination of cucurbitacin B in rat plasma: application to an absolute bioavailability study.

Authors:  Ya Xiao; Qiang Zhao; Qian Wu; Jinhua Chang; Hefei Xue; Cuizhe Liu; Xigang Liu
Journal:  RSC Adv       Date:  2018-09-05       Impact factor: 4.036

4.  Simultaneous Determination and Pharmacokinetics of Peimine and Peiminine in Beagle Dog Plasma by UPLC-MS/MS after the Oral Administration of Fritillariae ussuriensis Maxim and Fritillariae thunbergii Miq Powder.

Authors:  Zhibin Wang; Feng Cao; Yajun Chen; Zhenqiu Tang; Zhenyue Wang
Journal:  Molecules       Date:  2018-06-28       Impact factor: 4.411

5.  Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.

Authors:  Xiaoli Wang; Hua Li; Dong Li; Yudi Bai; Yao Zhang; Xue Yan; Jin Li; Ri Zhao; Jiahui Liu; Wei Liu; Maolin Shi; Cheng Xu; Tai Yang; Tao Zhang
Journal:  FEBS Open Bio       Date:  2020-11-27       Impact factor: 2.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.